

Yousef Zakharia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2145705/publications.pdf>

Version: 2024-02-01

83
papers

3,422
citations

218381

26
h-index

168136

53
g-index

86
all docs

86
docs citations

86
times ranked

4921
citing authors

#	ARTICLE	IF	CITATIONS
1	Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study. <i>European Urology Focus</i> , 2022, 8, 483-490.	1.6	1
2	A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 1-10.	0.9	4
3	Association of prior local therapy and outcomes with programmedâ€œdeath ligandâ€œ1 inhibitors in advanced urothelial cancer. <i>BJU International</i> , 2022, 130, 592-603.	1.3	3
4	Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 248-258.	5.1	73
5	Potential Role of Selenium in the Treatment of Cancer and Viral Infections. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2215.	1.8	22
6	Computerized Decision Support for Bladder Cancer Treatment Response Assessment in CT Urography: Effect on Diagnostic Accuracy in Multi-Institution Multi-Specialty Study. <i>Tomography</i> , 2022, 8, 644-656.	0.8	5
7	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	0.9	4
8	Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. <i>Cancer</i> , 2022, 128, 1194-1205.	2.0	26
9	Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103706.	2.0	3
10	MicroRNA Expression in Clear Cell Renal Cell Carcinoma Cell Lines and Tumor Biopsies: Potential Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5604.	1.8	1
11	Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 3248-3255.	3.2	24
12	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e440-e452.	0.9	10
13	Mapping the immune environment in clear cell renal carcinoma by single-cell genomics. <i>Communications Biology</i> , 2021, 4, 122.	2.0	139
14	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	1.3	18
15	Phase I with expansion clinical trial of seleno-L-methionine (SLM) in combination with axitinib in patients with relapsed clear cell renal cell carcinoma (ccRCC): Bench to bedside.. <i>Journal of Clinical Oncology</i> , 2021, 39, 322-322.	0.8	1
16	Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). <i>Cancer</i> , 2021, 127, 2204-2212.	2.0	32
17	Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy. <i>Cancers</i> , 2021, 13, 1489.	1.7	7
18	Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). <i>Oncologist</i> , 2021, 26, 560-e1103.	1.9	6

#	ARTICLE	IF	CITATIONS
19	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 525-537.	5.1	225
20	Detection of pro angiogenic and inflammatory biomarkers in patients with CKD. <i>Scientific Reports</i> , 2021, 11, 8786.	1.6	16
21	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	2.6	39
22	Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma. , 2021, 9, e002057.		39
23	Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease. <i>Annals of Translational Medicine</i> , 2021, 9, 1033-1033.	0.7	23
24	Current status of intralesional agents in treatment of malignant melanoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1038-1038.	0.7	21
25	Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. <i>Cancer Discovery</i> , 2021, 11, 2998-3007.	7.7	80
26	Race and ethnicity representation in clinical trials: findings from a literature review of Phase I oncology trials. <i>Future Oncology</i> , 2021, 17, 3271-3280.	1.1	24
27	CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells. <i>Nature Communications</i> , 2021, 12, 5764.	5.8	38
28	Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 1815.	3.4	40
29	Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity. <i>Immunity</i> , 2021, 54, 2354-2371.e8.	6.6	34
30	Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e157-e166.	0.9	21
31	A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , 2020, 25, 121-e213.	1.9	28
32	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	2.0	70
33	Quantitative Testâ€“Retest Measurement of ⁶⁸ Ga-PSMA-HBED-CC in Tumor and Normal Tissue. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1145-1152.	2.8	23
34	The clinical characteristics of melanoma with BRAF V600R mutation: a case series study. <i>Melanoma Research</i> , 2020, 30, 107-112.	0.6	6
35	Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies. <i>Antibiotics</i> , 2020, 9, 740.	1.5	11
36	Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). <i>Journal of Clinical Oncology</i> , 2020, 38, 4240-4248.	0.8	69

#	ARTICLE	IF	CITATIONS
37	Radioresistance in Glioblastoma and the Development of Radiosensitizers. <i>Cancers</i> , 2020, 12, 2511.	1.7	77
38	Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer. <i>Oncologist</i> , 2020, 25, e1711-e1719.	1.9	28
39	Understanding the Redox Biology of Selenium in the Search of Targeted Cancer Therapies. <i>Antioxidants</i> , 2020, 9, 420.	2.2	29
40	Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. , 2020, 8, e000538.		19
41	Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1606.	3.4	79
42	Immune checkpoint inhibitors in heart or lung transplantation: Early results from a registry initiative. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 604-606.	0.3	15
43	PARP Inhibitors in Prostate and Urothelial Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 114.	1.3	13
44	The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 143.	1.7	36
45	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.2	32
46	Obesity diminishes response to PD-1-based immunotherapies in renal cancer. , 2020, 8, e000725.		45
47	ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5015-5015.	0.8	17
48	Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	0.6	15
49	Ipilimumab-induced hypophysitis, a single academic center experience. <i>Pituitary</i> , 2019, 22, 488-496.	1.6	28
50	Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2019, 381, 338-348.	13.9	885
51	Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-5.	0.2	1
52	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 581-590.	5.1	124
53	Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma. <i>Melanoma Research</i> , 2019, 29, 643-647.	0.6	13
54	Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review. <i>Cancers</i> , 2019, 11, 1950.	1.7	24

#	ARTICLE	IF	CITATIONS
55	Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. <i>Seminars in Immunopathology</i> , 2019, 41, 41-48.	2.8	198
56	Advanced stage melanoma therapies: Detailing the present and exploring the future. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 99-111.	2.0	48
57	Preliminary results of phase I clinical trial of high doses of seleno-L-methionine (SLM) in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 660-660.	0.8	4
58	Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer. <i>Journal of Immunotherapy</i> , 2018, 41, 42-44.	1.2	17
59	Toxicities with targeted therapies after immunotherapy in metastatic melanoma. <i>Melanoma Research</i> , 2018, 28, 600-604.	0.6	10
60	Nonâ€Muscle Invasive Papillary Urothelial Carcinoma Metastatic to the Mandible. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2018, 6, 232470961880633.	0.3	2
61	Immunotherapy Advances in Urothelial Carcinoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 79.	1.3	5
62	Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3834.	1.8	31
63	Autoimmune retinopathy and optic neuropathy associated with enolase-positive renal oncocytoma. <i>American Journal of Ophthalmology Case Reports</i> , 2018, 12, 55-60.	0.4	7
64	Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 370.	1.3	91
65	Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces Together. <i>Journal of Immunotherapy</i> , 2018, 41, 359-360.	1.2	10
66	Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9512-9512.	0.8	35
67	Phase1 clinical trial of high doses of Seleno-L-methionine (SLM), in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 630-630.	0.8	6
68	Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development. <i>Oncotarget</i> , 2018, 9, 10765-10783.	0.8	29
69	Qualityâ€ofâ€life outcomes in patients with advanced melanoma: A review of the literature. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 511-520.	1.5	16
70	Ipilimumab: from preclinical development to future clinical perspectives in melanoma. <i>Future Oncology</i> , 2017, 13, 625-636.	1.1	31
71	Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 1175-1182.	2.0	14
72	Abstract CT117: Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma. <i>Cancer Research</i> , 2017, 77, CT117-CT117.	0.4	27

#	ARTICLE	IF	CITATIONS
73	Small bowel obstruction: a recurrence of melanoma during the second trimester of pregnancy. Proceedings in Obstetrics and Gynecology, 2017, 7, 1-7.	0.1	1
74	Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase Ib study. Oncotarget, 2017, 8, 89182-89193.	0.8	33
75	Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease. Journal of Investigative Medicine High Impact Case Reports, 2016, 4, 232470961667431.	0.3	40
76	IMCT-21UPDATES ON PHASE 1B/2 COMBINATION STUDY OF THE IDO PATHWAY INHIBITOR INDOXIMOD WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY MALIGNANT BRAIN TUMORS. Neuro-Oncology, 2015, 17, v112.2-v112.	0.6	7
77	Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma. Expert Opinion on Drug Discovery, 2015, 10, 925-935.	2.5	9
78	A phase 1b/2 study of the combination of the IDO pathway inhibitor indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors: Safety analysis and preliminary efficacy of the phase 1b component.. Journal of Clinical Oncology, 2015, 33, 2070-2070.	0.8	8
79	Ovarian Cancer from an Immune Perspective. Radiation Research, 2014, 182, 239-251.	0.7	3
80	Tumor Lysis Syndrome in a Retroperitoneal Sarcoma. Journal of Investigative Medicine High Impact Case Reports, 2014, 2, 232470961454234.	0.3	3
81	HER2 Testing. Applied Immunohistochemistry and Molecular Morphology, 2011, 19, 424-430.	0.6	4
82	Breast Hormonal Receptors Test Should Be Repeated on Excisional Biopsy After Negative Core Needle Biopsy. Breast Journal, 2011, 17, 180-186.	0.4	12
83	The effect of various vitamin D supplementation regimens in breast cancer patients. Breast Cancer Research and Treatment, 2011, 127, 171-177.	1.1	42